Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation

Bjoern F Kraemer, Robert A Campbell, Hansjörg Schwertz, Mark J Cody, Zechariah Franks, Neal D Tolley, Walter H A Kahr, Stephan Lindemann, Peter Seizer, Christian C Yost, Guy A Zimmerman, Andrew S Weyrich, Bjoern F Kraemer, Robert A Campbell, Hansjörg Schwertz, Mark J Cody, Zechariah Franks, Neal D Tolley, Walter H A Kahr, Stephan Lindemann, Peter Seizer, Christian C Yost, Guy A Zimmerman, Andrew S Weyrich

Abstract

Human β-defensins (hBD) are antimicrobial peptides that curb microbial activity. Although hBD's are primarily expressed by epithelial cells, we show that human platelets express hBD-1 that has both predicted and novel antibacterial activities. We observed that activated platelets surround Staphylococcus aureus (S. aureus), forcing the pathogens into clusters that have a reduced growth rate compared to S. aureus alone. Given the microbicidal activity of β-defensins, we determined whether hBD family members were present in platelets and found mRNA and protein for hBD-1. We also established that hBD-1 protein resided in extragranular cytoplasmic compartments of platelets. Consistent with this localization pattern, agonists that elicit granular secretion by platelets did not readily induce hBD-1 release. Nevertheless, platelets released hBD-1 when they were stimulated by α-toxin, a S. aureus product that permeabilizes target cells. Platelet-derived hBD-1 significantly impaired the growth of clinical strains of S. aureus. hBD-1 also induced robust neutrophil extracellular trap (NET) formation by target polymorphonuclear leukocytes (PMNs), which is a novel antimicrobial function of β-defensins that was not previously identified. Taken together, these data demonstrate that hBD-1 is a previously-unrecognized component of platelets that displays classic antimicrobial activity and, in addition, signals PMNs to extrude DNA lattices that capture and kill bacteria.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Platelets sequester S. aureus .
Figure 1. Platelets sequester S. aureus.
Cultured S. aureus were incubated in the presence or absence of platelets (240 minutes). At the end of this period, an equal volume of fixative was added to the suspension and the samples were prepared for confocal (A) or transmission electron (B) microscopy. (A) The left panel shows S. aureus (magenta - stained with topro-3) only. The middle panel displays the pattern of S. aureus (magenta) growth in the presence of platelets, which are not visible in this panel but shown in an overlay that is displayed in the far right panel (bacteria, magenta; platelets, green – stained with phalloidin). Scale bars = 5 µm. (B) Transmission electron microscopy of S. aureus in the presence (right panel) or absence (left panel) of platelets. Scale bars = 10 µm. (C) Differential interference contrast (left panel) and transmission electron (right panel) microscopy of clusters of S. aureus (arrows) surrounded by platelets. Scale bars = 5 µm. The panels in figure 1 are representative of three to four independent experiments. Sa, S. aureus; P, platelets.
Figure 2. Platelets impede the growth of…
Figure 2. Platelets impede the growth of S. aureus.
Cultured S. aureus were incubated in the presence or absence of platelets for 240 minutes and bacterial growth was then measured as described in Materials and Methods. (A) The blood agar plates are representative examples of four independent studies. (B) The bars in the lower panel represent the mean±SEM of the fold increase in S. aureus growth (240 minutes) in the presence or absence of platelets over baseline (horizontal line). The single asterisk indicates a significant increase (p<0.05) in growth over baseline. The double asterisks indicates a significant (p<0.05) reduction in S. aureus growth in the presence of platelets when compared to S. aureus growth by itself.
Figure 3. Platelets express and release β-defensin…
Figure 3. Platelets express and release β-defensin 1 in response to α-toxin.
(A) The curves show real-time PCR results for integrin αIIb and each of the defensin family members in platelets using the same template RNA. The inset shows semi-quantitative PCR for hBD-1, -2 and -3 in platelets and HeLa cells. This figure is representative of three independent experiments. (B) Immunocytochemical analysis of hDB-1 (green) and WGA in unstimulated platelets. Inset (top row, hBD-1): area selected for enlargement and merge. This figure is representative of five independent experiments. Scale bars = 5 µm. (C) hBD-1 protein in lysates and supernatants from platelets that were stimulated with α-toxin (50 ng/ml), thrombin (0.1 U/ml), TRAP (20 µM), or PAF (100 nM) for 30 minutes. The bars represent the mean±SEM of three independent experiments.
Figure 4. Platelet-derived β-defensin 1 inhibits the…
Figure 4. Platelet-derived β-defensin 1 inhibits the growth of S. aureus.
(A) S. aureus growth was determined in the presence of recombinant hBD-1 (400 ng/ml) or its vehicle. The bars represent the mean±SEM of the fold increase in S. aureus growth (240 minutes) over baseline (horizontal line). The single asterisk indicates a significant increase (p<0.05) in growth over baseline. The double asterisks indicates a significant (p<0.05) reduction in S. aureus growth in the presence of recombinant hBD-1 when compared to S. aureus incubated with its vehicle. (B) S. aureus growth in the presence of immunoprecipitates that were captured from platelet lysates incubated with anti-hBD-1 or its control IgG. The bars represent the mean±SEM of the fold increase in S. aureus growth (240 minutes) over baseline (horizontal line). The single asterisk indicates a significant increase (p<0.05) in the growth of S. aureus that was treated with IgG immunoprecipitates over baseline. The double asterisks indicates a significant (p<0.05) reduction in S. aureus growth in the presence of anti-hBD-1 immunoprecipitates when compared to IgG immunoprecipitates. (C) The growth of S. aureus in the absence or presence of platelets that were co-incubated with a neutralizing antibody against hBD-1 or its IgG control. The bars represent the mean±SEM of the fold increase in S. aureus growth (240 minutes) over baseline (horizontal line). The single asterisk indicates a significant increase (p<0.05) in the growth of S. aureus alone or S. aureus co-incubated with platelets and anti-hBD-1 over baseline. The double asterisks indicates a significant (p<0.05) reduction in S. aureus growth in the presence of platelets incubated with control IgG when compared to S. aureus alone or S. aureus co-incubated with platelets and anti-hBD-1.
Figure 5. β-defensin 1 induces NET formation…
Figure 5. β-defensin 1 induces NET formation by PMNs.
(A) NET formation in the presence of control immunoglobulin (left panel) or hBD-1 (right panel) immunoprecipitates that were captured from human platelets. The NETs (arrows) were detected by live cell imaging as previously described. (B) NET formation in untreated PMNs (control) or PMNs incubated with 100 ng/ml of recombinant hBD-1 alone or in the presence of anti-hBD-1 or its control IgG. Figure 5A and 5B are representative of three independent experiments.
Figure 6. β-defensin 1, but not other…
Figure 6. β-defensin 1, but not other β-defensin family members, induce PMNs to form NETs.
PMNs were left untreated (control) or incubated with 100 ng/ml of recombinant hBD-1, hBD-2, or hBD-3. After 60 minutes, NETs (arrows) were detected by live cell imaging as previously described. Increasing concentrations of hBD-2 or hBD-3 failed to induce NET formation (data not shown). Images are representative of three independent experiments.
Figure 7. β-defensin 1 mediated NET formation…
Figure 7. β-defensin 1 mediated NET formation is dependent on reactive oxygen species.
(A) PMNs were incubated with diphenylene iodonium (DPI) and then left untreated (control) or stimulated with 100 ngl/ml of LPS or hBD-1 for 1 hour. Images are representative of three independent experiments. (B) PMNs were left alone or treated with 100 ng/ml of LPS or recombinant hBD-1 for 1 hour and then stained with trypan blue to determine cell viability. (C) PMNs were left alone or incubated with 100 ng/ml of LPS or recombinant hBD-1. After 1 hour, neutrophil elastase activity was measured. The bar graph represents the percent increase in neutrophil elastase activity over untreated neutrophils. The bars in panel B and C represent the mean±SEM of three independent experiments.

References

    1. Durack DT. Experimental bacterial endocarditis. IV. Structure and evolution of very early lesions. J Pathol. 1975;115:81–89.
    1. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol. 2006;4:445–457.
    1. Yeaman M, Bayer, AS . Antimicrobial Host Defense. In: Michelson AD, editor. Platelets. San Diego: Elsevier Science; 2007. pp. 469–490.
    1. Yeaman MR, Puentes SM, Norman DC, Bayer AS. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect Immun. 1992;60:1202–1209.
    1. Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME. Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect Immun. 1997;65:1023–1031.
    1. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun. 2002;70:6524–6533.
    1. Tecle T, Tripathi S, Hartshorn KL. Review: Defensins and cathelicidins in lung immunity. Innate Immun. 2010;16:151–159.
    1. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997;88:553–560.
    1. Bals R, Wang X, Wu Z, Freeman T, Bafna V, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest. 1998;102:874–880.
    1. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985;76:1427–1435.
    1. Selsted ME, Miller SI, Henschen AH, Ouellette AJ. Enteric defensins: antibiotic peptide components of intestinal host defense. J Cell Biol. 1992;118:929–936.
    1. Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24:202–208.
    1. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci. 2006;63:1294–1313.
    1. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2005;6:551–557.
    1. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–1535.
    1. Yost CC, Cody MJ, Harris ES, Thornton NL, McInturff AM, et al. Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood. 2009;113:6419–6427.
    1. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13:463–469.
    1. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005;122:379–391.
    1. Schwertz H, Tolley ND, Foulks JM, Denis MM, Risenmay BW, et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets. J Exp Med. 2006;203:2433–2440.
    1. Schwertz H, Koster S, Kahr WH, Michetti N, Kraemer BF, et al. Anucleate platelets generate progeny. Blood. 2010;115:3801–3809.
    1. Lindemann S, Tolley ND, Eyre JR, Kraiss LW, Mahoney TM, et al. Integrins regulate the intracellular distribution of eukaryotic initiation factor 4E in platelets. A checkpoint for translational control. J Biol Chem. 2001;276:33947–33951.
    1. Kerrigan SW, Clarke N, Loughman A, Meade G, Foster TJ, et al. Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. Arterioscler Thromb Vasc Biol. 2008;28:335–340.
    1. Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol. 2006;59:212–230.
    1. O'Brien L, Kerrigan SW, Kaw G, Hogan M, Penades J, et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol. 2002;44:1033–1044.
    1. Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Krol W, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an in vitro study. J Bone Joint Surg Br. 2007;89:417–420.
    1. Koo SP, Yeaman MR, Bayer AS. Staphylocidal action of thrombin-induced platelet microbicidal protein is influenced by microenvironment and target cell growth phase. Infect Immun. 1996;64:3758–3764.
    1. Reed GL. Platelet Secretion. In: Michelson AD, editor. Platelets. San Diego: Elsevier Science; 2007. pp. 181–195.
    1. Kim JA, Jung YJ, Seoh JY, Woo SY, Seo JS, et al. Gene expression profile of megakaryocytes from human cord blood CD34(+) cells ex vivo expanded by thrombopoietin. Stem Cells. 2002;20:402–416.
    1. Bensch KW, Raida M, Magert HJ, Schulz-Knappe P, Forssmann WG. hBD-1: a novel beta-defensin from human plasma. FEBS Lett. 1995;368:331–335.
    1. Fang XM, Shu Q, Chen QX, Book M, Sahl HG, et al. Differential expression of alpha- and beta-defensins in human peripheral blood. Eur J Clin Invest. 2003;33:82–87.
    1. Tohidnezhad M, Varoga D, Podschun R, Wruck CJ, Seekamp A, et al. Thrombocytes are effectors of the innate immune system releasing human beta defensin-3. Injury. 2011;42:682–686.
    1. Supp DM, Karpinski AC, Boyce ST. Expression of human beta-defensins HBD-1, HBD-2, and HBD-3 in cultured keratinocytes and skin substitutes. Burns. 2004;30:643–648.
    1. Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol. 2010;87:79–92.
    1. Pawar P, Shin PK, Mousa SA, Ross JM, Konstantopoulos K. Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. J Immunol. 2004;173:1258–1265.
    1. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood. 2002;99:4021–4029.
    1. White JG. Why human platelets fail to kill bacteria. Platelets. 2006;17:191–200.
    1. Alexander EH, Hudson MC. Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl Microbiol Biotechnol. 2001;56:361–366.
    1. Yeaman MR, Norman DC, Bayer AS. Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob Agents Chemother. 1992;36:1665–1670.
    1. Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, et al. Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol. 1999;106:391–399.
    1. Bayer AS, Ramos MD, Menzies BE, Yeaman MR, Shen AJ, et al. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect Immun. 1997;65:4652–4660.
    1. Yeaman MR, Bayer AS, Koo SP, Foss W, Sullam PM. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest. 1998;101:178–187.
    1. Ashmarin IP, Tkachenko SB, Rud'ko IA, Korneva EA, Kokriakov VN, et al. Effect of defensin on platelet functional activity. Biull Eksp Biol Med. 1993;115:23–25.
    1. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999;286:525–528.
    1. Boniotto M, Jordan WJ, Eskdale J, Tossi A, Antcheva N, et al. Human beta-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells. Antimicrob Agents Chemother. 2006;50:1433–1441.
    1. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Spencer ED, Dixon DA, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005;111:633–642.
    1. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525–1534.
    1. Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost. 2008;6:415–420.
    1. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus. J Immunol. 2010;185:7413–7425.
    1. Schmidt R, Bultmann A, Fischel S, Gillitzer A, Cullen P, et al. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res. 2008;102:302–309.

Source: PubMed

3
Tilaa